Search Orphan Drug Designations and Approvals
-
| Generic Name: | recombinant fusion protein composed of a high affinity MHC class II binding motif fused to an optimized peptide sequence derived from human CD33 |
|---|---|
| Date Designated: | 10/17/2025 |
| Orphan Designation: | treatment of acute myelogenous leukemia |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Leukogene Therapeutics, Inc. 4120 Whiting St. Mt. Pleasant, South Carolina 29466 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







